Northwest Biotherapeutics Inc (QB) (NWBO) Quote

"Franchise" was mentioned in their PR. Whether that means a commercial franchise or a term for their vaccine platform is the basis for speculation, but a commercial franchise could certainly be implemented... and would make perfect sense.

You’re getting paid or you wouldn’t keep responding.😂

Someone said something about franchise(s)…

Big Pharma and FDA by the numbers,
There is a war going on and it appears that the guns are facing towards NWBO and the Biotherapeutics industry, IMPO. Here are some helpful links to support the fact that this war is ongoing and has a direct correlation with NWBO, IMPO.

https://www.nytimes.com/2022/09/15/health/fda-drug-industry-fees.html

F.D.A.’s Drug Industry Fees Fuel Concerns Over Influence
The pharmaceutical industry finances about 75 percent of the agency’s drug division, through a controversial program that Congress must reauthorize by the end of this month. If the FDA's main drug funds come from the pharmaceutical industry with finances about 75 percent, why would they support NWBO?

https://www.forbes.com/sites/johnlamattina/2022/09/22/why-is-biopharma-paying-75-of-the-fdas-drug-division-budget/?sh=1e6aaf207480

https://www.usatoday.com/story/news/factcheck/2021/08/27/fact-check-some-fdas-budget-does-come-industry-funding/5572076001/

https://time.com/6257866/big-pharma-patent-abuse-drug-pricing-crisis/

https://prospect.org/coronavirus/big-pharmas-game-of-control-covid-drug-treatment/

Why wasting time writing to Congress person may not be worth the effort?
"More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows"
https://www.statnews.com/feature/prescription-politics/federal-full-data-set/

https://www.statista.com/topics/1719/pharmaceutical-industry/#topicOverview

https://www.statista.com/topics/1764/global-pharmaceutical-industry/#topicOverview
https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/

https://mises.org/mises-wire/legacy-corruption-fda-and-big-pharma

NWBO has the opportunity to win this battle by being approved and allowed to help cure cancer, IMPO.

wow, .... you are in for a major disappointment. IMO

Authors of the JAMA published journal:

🌟 Linda M. Liau, MD, PhD1; Keyoumars Ashkan, MD, FRCP, FRCS2; Steven Brem, MD3; Jian L. Campian, MD, PhD4; John E. Trusheim, MD5; Fabio M. Iwamoto, MD6,7; David D. Tran, MD, PhD8; George Ansstas, MD9; Charles S. Cobbs, MD10; Jason A. Heth, MD11; Michael E. Salacz, MD12; Stacy D’Andre, MD13; Robert D. Aiken, MD14; Yaron A. Moshel, MD, PhD14; Joo Y. Nam, MD15; Clement P. Pillainayagam, MD16; Stephanie A. Wagner, MD17; Kevin A. Walter, MD18; Rekha Chaudhary, MD19; Samuel A. Goldlust, MD20; Ian Y. Lee, MD21; Daniela A. Bota, MD, PhD22; Heinrich Elinzano, MD23; Jai Grewal, MD24; Kevin Lillehei, MD25; Tom Mikkelsen, MD, FRCPC21; Tobias Walbert, MD21; Steven Abram, MD26; Andrew J. Brenner, MD, PhD27; Matthew G. Ewend, MD28; Simon Khagi, MD29; Darren S. Lovick, MD30; Jana Portnow, MD31; Lyndon Kim, MD32; William G. Loudon, MD33; Nina L. Martinez, MD34; Reid C. Thompson, MD35; David E. Avigan, MD36; Karen L. Fink, MD, PhD37; Francois J. Geoffroy, MD38; Pierre Giglio, MD39; Oleg Gligich, MD40; Dietmar Krex, MD41; Scott M. Lindhorst, MD42; Jose Lutzky, MD43; Hans-Jörg Meisel, MD, PhD44; Minou Nadji-Ohl, MD45; Lhagva Sanchin, MD44; Andrew Sloan, MD46; Lynne P. Taylor, MD47; Julian K. Wu, MD47; Erin M. Dunbar, MD48; Arnold B. Etame, MD, PhD49; Santosh Kesari, MD, PhD50; David Mathieu, MD51; David E. Piccioni, MD, PhD52; David S. Baskin, MD53; Michel Lacroix, MD54; Sven-Axel May, MD55; Pamela Z. New, MD56; Timothy J. Pluard, MD57; Steven A. Toms, MD58; Victor Tse, MD59; Scott Peak, MD59; John L. Villano, MD, PhD60; James D. Battiste, MD, PhD61; Paul J. Mulholland, MD62; Michael L. Pearlman, MD63; Kevin Petrecca, MD, PhD64; Michael Schulder, MD65; Robert M. Prins, PhD66; Alton L. Boynton, PhD67; Marnix L. Bosch, PhD67


Authors of your sciencedirect.com opinion piece:

🫴 T. Olivier, D. Migliorini

Pubmed Disclaimer: The presence of any article, book, or document in these databases does not imply an endorsement of, or concurrence with, the contents by NLM, the National Institutes of Health (NIH), or the U.S. Federal Government.

You posted a big nothing burger.

CO, by the time they're qualified to uplist, neither major exchange will care that while on the OTC they failed to have an Annual Meeting in 2023. Frankly at $4 or more they'll represent a company with a market cap of over $5 billion, far bigger than most companies at the time they apply to be on these exchanges. They will be a very different company than they are today.

As for a BP or other partner being necessary to grow, frankly with the right contracts for commercially manufacturing, storing, and distributing their vaccines, it's their contractors who could be doing the lions share of the work. I believe that Advent will be well positioned to do this for all of Europe, and CRL could potentially do it in most, if not all, the remainder of the world. It's up to the company how they want to go about this, but once the EDEN is available in mass the bulk of the business can be in the hands of these contractors. Tracking every disposable cassette from the time it's created until it's recycled will give them an audit trial for every batch of vaccine.

I'm not saying this is how they'll operate, they may grow dramatically and do it themselves. With a dramatically higher stock price and hundreds of millions of authorized shares still available to them, they could raise billions without asking shareholders to authorize more shares, so such explosive building growth is possible. Personally I believe they want to develop a huge market cap without becoming a huge company, with the EDEN approved and good contracts, they could do this with limited corporate growth.

I'm just suggesting that they have many choices. With approval, I believe they'll initiate both trials with DCVax-Direct to work it toward tumor agnostic approval, and on new trials for DCVax-L leading to a label change that's tumor agnostic. If they manage these trials, and allow contractors to handle the commercial manufacturing, storage, distribution and sales of DCVax-L they'll be well positioned for explosive growth. Of course they'll also be working for approval from all authorities, first the other three in the trial, but then expansion throughout the globe. Again, they'll use contractors in creating the changes needed to what's been created in approaching the UK.

Gary

This is excellent DD.

Manibiotech that is also my hope and thinking. I think it is best to get an approval and pass it off to a company (or partner) with much greater resources

your being paid, no doubt.

You need to recalibrate your instinct, as it’s so way off, you must exist in another dimension!

If that were true then nwbo would be increasing in price, some day perhaps

novocure getting walked down, 12.46, they know why

I really don't know why age is brought up as an issue. This is especially true with our two major political parties selecting the oldest candidates in our history to run for President. There is no management position where the current holder of the position is irreplaceable if they either wished to retire, or if conditions demanded it.

LP deserves to take the company as far as she cares to, she's run the gauntlet and is closing in on tremendous success. If at some point she wished to retire, or diminish her duties, she certainly doesn't need to sell the company. A new CEO can be found, perhaps she'd want to be chairman of the board. The point is, she, and all other key people there, are replaceable without a buyout of the company.

With the UK approval, money will almost certainly not be an issue for those in management, or for many of us for that matter. A decision to retire or diminish their efforts won't be monetarily based, it will be based on their personal goals, and desires. As long as they enjoy doing what they're doing, and are in good health, they'll probably remain.

Many investors believe that with success NWBO needs to be substantially larger. They've gotten this far with contracting out much of what they've needed to get done, I believe they will grow, but they could also choose to contract out even more, possibly to a BP that partners with them.

Gary

Why do you care so much? Like, you think your going to make a difference-lol
You’re getting paid, it’s the only logical reason why you and the others spend day and night bashing NWBO. I’ll admit there are ones who carry it to far the other way but you guys, your being paid, no doubt.

I hear that Cambridge, England has some nice homes.

That’s exactly why I think they have no intention to do it alone , otherwise with what face will they go for uplisting. They are just waiting for approval . And then there is their age .

If I am to be paid, I’ll ask for it not to be in NWBO shares ☝️😂

Seriously, it is utterly delusional to believe that I and some others are paid for posting !
But I suppose that symptomatic of being starved of information from NWBO, which I do actually sympathise with. It’s must be maddening, when you have your own hard earned cash at risk.

Consequentially, you are all just left to your own imaginations to create your individually tailored comforting cause and effect narrative(s)./ blanket.

You're right, it made little difference to the stock price. I do however believe it got a lot of attention from the thousands of oncologists, etc. who attend ASCO for information, few of them are investors. I would be surprised if more than a couple percent who looked at the webcast from the Experts Theater weren't already investors, or at least knowledgeable of NWBO before the conference.

If we have an approval before, the publicity about that may attract far more to attend the webcast, and probably attract many attending ASCO to attend live. Without approval, Newman may be right, they'd cancel, but I believe they would still pay and frankly I still think it's an opportunity to discuss where we are, and where we're going. If I'm right that they'd lose the funds committed to the presentation, I think they'll present.

ASCO Abstract Titles are scheduled to be released on April 24th so if anything has been submitted, we could learn about it then, the actual Abstracts are issued May 23rd. The ASCO Conference is from May 31st to June 4th.

Gary

Yeah but what decade?

Is it possible to build a 2 billion share short position in a stock with 1.2 billion shares outstanding. How is it done.
ChatGPT
Building a short position larger than the total number of shares outstanding for a stock is theoretically possible through various mechanisms. Here's how it could potentially be done:

Synthetic Shorting: Investors can create synthetic short positions through derivatives like options and futures. For instance, they could buy put options or sell call options on the stock. By doing so, they can effectively bet on the stock's decline without owning the actual shares. Theoretically, there's no limit to the number of options contracts that can be traded, so someone could accumulate a substantial short position this way.

Borrowing and Rehypothecation: Institutional investors or hedge funds with significant capital and borrowing power can borrow shares from multiple sources, including other institutions, brokerage firms, or even retail investors who lend out their shares through margin accounts. They can then sell these borrowed shares in the market, effectively shorting the stock. The process of re-lending borrowed shares to multiple parties, known as rehypothecation, can create situations where more shares are shorted than are actually outstanding.

Margin Trading: In margin trading, investors can borrow funds from their broker to buy or sell securities. If an investor has a large enough margin account, they can potentially short a significant amount of shares beyond what they actually possess.

Dark Pools and Over-the-Counter (OTC) Markets: Some trades, especially large ones, may occur in dark pools or over-the-counter markets, away from public exchanges. These markets often operate with less transparency and regulatory oversight, potentially allowing for the accumulation of very large short positions.

Synthetic Derivatives: Sophisticated investors can also use complex financial instruments to create synthetic short positions. For instance, they might enter into swap agreements or other derivatives contracts that effectively mimic the payoff of a short position without directly borrowing or selling the underlying shares.

It's worth noting that accumulating such a massive short position would likely attract significant attention from regulators and market participants. Additionally, executing such a strategy carries substantial risks, as short positions have unlimited potential losses if the stock price rises instead of falls.
____________________________________________________________________________________________

I don't believe we have the options or other derivatives available that Chat spoke of, but their answer does make it sound possible. I don't know if there are option markets that normal investors cannot invest in, but certain investors may, anyone have a feel for that.

Gary

skitahoe you stated "If the company does what it's done in the past at ASCO, they'll have one of the larger exhibitors booth, and they'll have an hour to present at the Experts Theater, which has been webcast in the past"

. And what game changing news came out of the LARGE BOOTH and EXPERTS THEATER ?

"NOT A DAMN THING"

There is no doubt in my mind that all the bashers like inquirig, nemesis18 and others while bashing NWBO and getting paid to do so, they own shares of NWBO. They may be annoying but there not stupid.-lol
Maybe a little careless at times with their comments but not stupid-lol

For those who have insidious motives, here is something you need to pay special attention.

The following is the official address of Oncovir according to linkedin. It is a home office. The owner of Oncovir sold his house for $2.4m in 2021 and currently pays rent. Who would sold his house for something whose patent is expired already? I suspect the things about to happen must be enormous otherwise it cannot explain why the owner would sell his beautiful house for it.

https://www.linkedin.com/company/oncovir/about/

3203 Cleveland Ave Nw, Washington, District of Columbia 20008, US

yes calm before storm, imo; no Expert Theatre this time I think; if no approval by ASCO, just in a Q period, I guess.

April looking good!!
Awesome work

LOL. How about focusing on acquiring Advent first. Speaking of which, what keeps an Advent competitor from taking a major position in NWBO?

Don’t you feel like you’ve been waiting outside a empty house, devoid of all carpets and furniture, with all services and phone lines cut.in the pissing rain .
Desperately hoping the owners will return one day, to let you in ?

I hope you have a really good editor for your book because by golly you don't write too goodly.

Is this the calm before the storm?

We all seem to be set in our positions, waiting to see what the UK does, waiting to see the status of the EDEN unit, waiting to see when the company announces an Annual Meeting, etc.

Nothing we say can change any of this, but we all have our opinions of what's happening, but the facts must come from the regulators, and the company.

I'll restate my belief that the UK will approve on time, but I'll admit not knowing if on time to them now means 120 days, or if 150 days remains the target for this decision on their part. Early next week we're at the 120 day point, if nothing has been heard from the UK, I'll assume that they're looking at one month later. A decision can be made on any day, the company should be notified, then I believe they would have up to 4 days to notify investors based on SEC regulations. To me, if a positive decision cannot be announced by the open on Wednesday, I'd prefer it be held till at least the weekend, and rolled out in a way that maximizes attention to it. Other than an Annual Meeting or Expert Theater presentation at ASCO I cannot remember when the company has spoken to investors, or the general investment public. I have recently seen other companies get both good and bad trial news or regulatory decisions, in each case a webcast was announced at the same time the news was announced. I would hope that NWBO would have the same respect for investors and hold a webcast shortly after the news, good or bad. As a West Coast investor I prefer such webcasts during the market day, but I recognize that they're often held before the open. On more than one occasion the news was announced roughly one to two hours before the open and the webcast made a half hour to an hour after the announcement, I very much doubt that most investors were aware of it when it was live, but such webcasts should almost immediately be available for replay on the company website.

Speaking of the Experts Theater at ASCO, I would believe that once again the company will present there. What they have to say may largely depend on what does, or doesn't happen between now and then. I don't know if Abstracts were submitted for peer reviewed presentations of any of the other trials at UCLA, or elsewhere, but it's possible. Abstracts are due early February, new data may be added to the actual presentation, but submission must be timely. The Experts Theater isn't considered peer reviewed, but information that's right up to the minute can be presented there. If the company does what it's done in the past at ASCO, they'll have one of the larger exhibitors booth, and they'll have an hour to present at the Experts Theater, which has been webcast in the past.

Gary

Now that’s funny-lol

attilathehunt There you go again, spreading your worthless predictions. Don't you ever learn? Your posts should come with some type of warning that you are a pumper and can never back up your predictions with facts.

Quick question:

Is it a crime in UK for someone impersonating as a former military member for financial gains? I suspect it is.

Professor Esteban Celis is Scientific Advisor of Oncovir who wrote plenty papers with Dr. Dmitry Gabrilovich--Chief Scientist, Cancer Immunology at AstraZeneca. Note that Dr. Dmitry Gabrilovich is an expert on dendritic cells too. The following are some of the papers they wrote together. I suspect the list is more persuasive than the fact that AZN's headquarter is close to Sawston manufacturing facility.

https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/tumour-microenvironment.html

Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy
https://www.cell.com/cancer-cell/pdf/S1535-6108(22)00393-2.pdf

HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
https://rupress.org/jem/article/207/11/2439/40663/HIF-1-regulates-function-and-differentiation-of

Lipid accumulation and dendritic cell dysfunction in cancer
https://www.nature.com/articles/nm.2172

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
https://www.jci.org/articles/view/40269

Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
https://journals.aai.org/jimmunol/article/184/6/3106/82771

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
https://www.jci.org/articles/view/45862

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis
https://www.jci.org/articles/view/74056

Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer
https://www.nature.com/articles/s41467-017-02186-9

Consensus nomenclature for CD8+ T cell phenotypes in cancer
https://www.tandfonline.com/doi/full/10.1080/2162402X.2014.998538

Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
https://aacrjournals.org/cancerres/article/72/21/5483/576215/Autophagy-Induced-by-Conventional-Chemotherapy

Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells
https://rupress.org/jem/article/212/3/351/41764/Immature-myeloid-cells-directly-contribute-to-skin

ER stress response regulates the fate of myeloid-derived suppressor cells through TRAIL receptors mediated apoptosis (TUM4P.907)
https://journals.aai.org/jimmunol/article/192/1_Supplement/138.8/53853

Abstract 5599: Novel mechanism of synergistic effect of cancer immunotherapy and chemotherapy
https://aacrjournals.org/cancerres/article/70/8_Supplement/5599/566350/Abstract-5599-Novel-mechanism-of-synergistic

Hopefully, NWBO makes a move to somehow acquire Oncovir in the future.


It will happen before approval and before BP deal....This will only strengthen the offer.

Perhaps the ASM will set the stage.

Hopefully, NWBO makes a move to somehow acquire Oncovir in the future.

With how their product greatly enhances DCVax-L, an acquisition of that nature would be tremendous, especially so when the publication for the combo trail comes out.

Here is the new board member of Oncovir. When did he join the company? Was that around the time the JAMA paper was submitted? For those on the other side of the fence, without doubt, you are going to lose. It is just the matter of how pathetic your loss is. I suspect it is going to huge. I have Boma available free of charge for those who are homeless.

Brian W. Pusch, JD

Board Member and Legal Consultant

Brian W. Pusch serves as Chairman of the Board and Chief Executive Officer of Microbes, Inc., a biotechnology that pioneered the use of beneficial bacteria and other microorganisms to improve plant agriculture and enhance crude oil recovery. He co-founded Inozyme Pharma, Inc., Opna Bio SA, and Xiconic Pharmaceuticals, LLC and serves on the boards of Evrys Bio, Invivo Sciences, Opna Bio and Xiconic Pharmaceuticals. He co-founded Quantum Circuits, Inc., a quantum computer company.

After a successful career, first as an associate and then as a partner, of a leading Wall Street law firm, in 1992 Mr. Pusch founded Pusch & Gal, a New York City boutique corporate finance law firm. He has been involved in founding, financing, and advising biotechnology and technology companies for nearly 40 years, including successful exits ranging from $500 million to $6.8 billion. He received an A.B. from The College of William & Mary in 1976 and a J.D. from the University of Virginia School of Law in 1979.

Don’t you feel like you’ve been waiting outside a empty house, devoid of all carpets and furniture, with all services and phone lines cut.in the pissing rain .
Desperately hoping the owners will return one day, to let you in ?

JAMA . DOES. NOT. APPROVE. DRUGS. !!!
JAMA . DOES. NOT. APPROVE. DRUGS. !!!
JAMA . DOES. NOT. APPROVE. DRUGS. !!!
It is therefore disappointing that due to key methodological limitations, the DCVax-L trial ultimately failed to provide sound conclusions about the potential efficacy of such approach for patients with glioblastoma.

https://pubmed.ncbi.nlm.nih.gov/37012085/

Maybe they're trying to reset the 13 month clock. Who knows.
Supposedly, violating the guidelines does not bode well for an up listing ? Or... If they are going to be bought/merged whatever happens under the old entity is moot.

I'm not saying any of that is going to happen, just thinking of scenarios.

$NWBO didn't start Advent. Linda Powers owns Advent thru her Toucan investment fund. $NWBO is a manufacturing customer of Advent. The money goes to Linda. You should read NWBO's SEC filings more closely. Sawston --> pic.twitter.com/o30wVW6oYb— Adam Feuerstein ✡️ (@adamfeuerstein) March 17, 2021

Great work Dstock.

No 100% disagree. What’s important to shareholders are milestones achieved such as MHRA approval not the date of the ASM.
Second, what’s important to shareholders is effective communications including target dates for milestones.
Whether they hit target dates is a separate discussion.
Third, they can hold the ASM regardless of whether approval is in hand. We have words like imminent to use should ASM precede approval. Besides, there are other milestones besides approval that are relevant like Eden’s readiness and target date for device approval.
Last, per PRs or the 10k we learned that once the MHRA process has been cemented there’s material collaborations involving additional trials or other. LP also indicated that the sole focus will be on the MHRA process and nothing else.
So to me, there is no other resources to devote to anything but the approval process. Since this is an available time issue and an ASM is announced then time resources have become available and the infamous cement has cured.
My opinion is better than yours LoL.

Here are all the clinical trials related to poly-iclc. Has anyone gone through the list? I have and I even read some of the papers related to some of the trials. As a matter of fact, the patent of poly-iclc expired last year without any FDA approval after so many trials.

https://classic.clinicaltrials.gov/ct2/results?cond=&term=Poly-ICLC&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=

But the President of Oncovir made the claim that 2024 would be a breakthrough year for Oncovir. The exciting part is that we will see how exciting it is probably in one month. My reasoning for one month is that he said additional data on t cell expansion and infiltration would come in the next few weeks. One month after his post, Oncovir released AACR present on prostate cancer. I suspect data on DCVax-L in combination with poly-iclc should be the next.

Our T cell expansion and tumor infiltration story is supported by additional data coming out in the next few weeks.

Yap yap yap…STFU
If I was a basher, I would be looking for

A- another job
B- another company to destroy
C- a very good lawyer

I may be wrong, but I think that they will hold one meeting for the year. They may call it what they wish, but I doubt if we will have one meeting for 2023 and another for 2024.

Gary

How much?

I googled JMHO and it says “Just My Herpes Outbreak”

You should not post when you are having a flare up!

swear to God, ASM s coming; I just heard it from God. Hahaha I guess the mfrs and shorts bad guys are toast now.

I agree with these statements, especially initially after MHRA approval of DCVax-L:

my guess is the reimbursement will be the same whether it’s made via artisan or closed system automated. Only the profit margin would change for NWBO/Flaskworks, and perhaps Advent, imo

Initially, Flaskworks approval and integration into the DCVax-L manufacturing processes, by the MHRA, will primarily impact NWBio’s ability to scale and meet demand capacity.

I believe the initial cost of DCVax-L will be in the $200,000 to $250,000 range, for up to 3 or more years of DCVax-L doses.

Then, after growth in demand and sales volumes, NWBio will eventually realize some economies of scale. Then the cost of DCVax-L will decrease.

The rate of decrease in DCVax-L cost will accelerate even more, after DCVax-L is approved and Flaskworks is incorporated, in other markets like Canada, the EU and the US.

If they announce ASM 2023 soon, the market will like it a lot.
Management won't show up empty handed, I'll bet you all the money you want.

Few bet in October 2023 that NWBO would have announced that they would be submitting to MHRA within time frame and then go back on that, but they did it. The logic was that they wouldn’t dare do another September/October 2020-style let down.

It is best for shareholders that NWBO announce the ASM date after MHRA approval is announced because otherwise and that is what seems to be happening. If they cannot learn to project time and then execute within doable timeframes then their fallback is to pretty much not give meaningful guidance. The fallback makes even more sense since MHRA has control of how long things take.

JFR161162 What do you wanna bet that they will show up at the 2023 ASM with nothing new to announce.
Another friggin genius on the this board. We got a million of them...